- Home
- AU vs QGEN Comparison
AU vs QGEN Comparison
Compare AU & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- QGEN
- Stock Information
- Founded
- AU 1944
- QGEN 1986
- Country
- AU United States
- QGEN Netherlands
- Employees
- AU N/A
- QGEN N/A
- Industry
- AU Precious Metals
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AU Basic Materials
- QGEN Health Care
- Exchange
- AU Nasdaq
- QGEN Nasdaq
- Market Cap
- AU 10.3B
- QGEN 9.5B
- IPO Year
- AU 1972
- QGEN 1996
- Fundamental
- Price
- AU $23.61
- QGEN $45.03
- Analyst Decision
- AU Hold
- QGEN Buy
- Analyst Count
- AU 5
- QGEN 8
- Target Price
- AU $31.75
- QGEN $52.29
- AVG Volume (30 Days)
- AU 4.4M
- QGEN 795.5K
- Earning Date
- AU 11-07-2024
- QGEN 02-04-2025
- Dividend Yield
- AU 0.93%
- QGEN 2.93%
- EPS Growth
- AU N/A
- QGEN N/A
- EPS
- AU 1.34
- QGEN 0.41
- Revenue
- AU $5,299,000,000.00
- QGEN $1,966,174,000.00
- Revenue This Year
- AU $31.43
- QGEN $2.73
- Revenue Next Year
- AU $27.65
- QGEN $5.55
- P/E Ratio
- AU $17.62
- QGEN $108.68
- Revenue Growth
- AU 17.78
- QGEN 0.62
- 52 Week Low
- AU $15.80
- QGEN $39.03
- 52 Week High
- AU $32.57
- QGEN $47.44
- Technical
- Relative Strength Index (RSI)
- AU 40.40
- QGEN 57.17
- Support Level
- AU $23.20
- QGEN $43.78
- Resistance Level
- AU $23.90
- QGEN $45.20
- Average True Range (ATR)
- AU 0.64
- QGEN 0.75
- MACD
- AU -0.10
- QGEN -0.04
- Stochastic Oscillator
- AU 12.89
- QGEN 51.34
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).